Bisphosphonate
Risk for osteonecrosis of the jaw higher with denosumab vs. bisphosphonates
Adults with osteoporosis have a higher risk for developing osteonecrosis of the jaw with denosumab therapy compared with bisphosphonates, according to study findings published in the Journal of Bone and Mineral Research.
Benefits of bisphosphonates outweigh atypical femur fracture risk in women
The reduced risks for osteoporotic and hip fractures with bisphosphonate therapy outweigh increased risk for atypical femur fractures for older women, according to study finding published in Bone.
Bisphosphonate therapy may prevent fracture in postmenopausal women with osteoporosis
Despite potential side effects, bisphosphonate therapy may benefit postmenopausal women with osteoporosis by preventing fractures, according to a study published in JAMA Internal Medicine.
Exercise builds bone strength during menopause
Postmenopausal women with low bone mass saw greater gains in spine bone mineral density and less bone turnover when assigned monthly risedronate therapy compared with a 12-month regimen of impact and resistance exercises, study data show.
Osteoporosis drug initiation may lower mortality risk in adults with epilepsy
Adults with epilepsy who initiated any osteoporosis drug therapy had a lower 3-year mortality risk compared with those who did not take a medication, according to study data published in Bone.
Bisphosphonates may lower risk for invasive breast cancer among women with DCIS
Bisphosphonate use among women with a history of ductal carcinoma in situ appeared associated with lower risk for subsequent invasive breast cancer, according to study results published in Cancer Research.
Risk score created to identify atypical vs. typical femur fractures in women
A model factoring in age, femoral neck width and lateral cortical width at lesser trochanter may be able to differentiate atypical vs. typical femur fractures in women, according to study data.
CKD progression risk ‘modest’ with bisphosphonate use
Adults with chronic kidney disease stage 3b were more likely to experience a worsening of renal function when prescribed bisphosphonate therapy, according to a database analysis published in the Journal of Bone and Mineral Research.
Atypical femur fracture data support bisphosphonate ‘drug holiday’ after 5 years
Risk for atypical femur fractures with bisphosphonate therapy, while rare, was strongly associated with duration of use beyond about 5 years and was quickly and dramatically reduced after discontinuing, study data show.
Nitrogen-containing bisphosphonates reduce pneumonia risk, mortality after hip fracture
Older adults prescribed nitrogen-containing bisphosphonate therapy after a hip fracture were less likely to develop pneumonia or die from the infection compared with similar adults who received no osteoporosis therapy, researchers report.